• NextPlat’s third-quarter 2026 net loss attributable to common stockholders narrowed 66% year-over-year to $748,000.
• Revenue fell 24% year-over-year to $10.5 million, reflecting lower healthcare reimbursement rates and retail prescription volumes.
• Gross margin reached 35%, while pharmacy contract revenue quadrupled year-over-year to approximately $2.4 million.
• A nationwide medication fulfillment website remains scheduled to launch in the fourth quarter, expanding PharmcoRx’s reach beyond Florida.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextPlat Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: FL96096) on November 12, 2026, and is solely responsible for the information contained therein.